Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK R&D President Patrick Vallance On Increasing R&D Productivity: An Interview With PharmAsia News (Part 2 of 2)

This article was originally published in PharmAsia News

Executive Summary

An R&D model aimed at bringing the pressure and promise of startups to life within GlaxoSmithKline PLC continues to be tweaked, according to Patrick Vallance, president of pharmaceuticals R&D. He sat down with PharmAsia News during a recent visit to Singapore to give an overview of the company’s strategy.

Advertisement

Related Content

GSK’s Breo Ellipta Gets “Snowquestered” As FDA Delays Advisory Cmte
GSK Is Getting Ready For A Return To The ’90s
Glaxo Confident In Output From Its Revamped R&D Engine
GSK Offers a Window Into Attempts at Biotech-like R&D
Further Mixed Results For GSK/Theravance’s Relovair Have Investors Holding Breath

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC084012

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel